Citigroup Has Lowered Expectations for Insulet (NASDAQ:PODD) Stock Price

Insulet (NASDAQ:PODD) had its price objective reduced by analysts at Citigroup from $175.00 to $165.00 in a research report issued on Thursday,MarketScreener reports. The brokerage currently has a “neutral” rating on the medical instruments supplier’s stock. Citigroup’s price target suggests a potential upside of 13.01% from the stock’s current price.

Other analysts have also recently issued reports about the stock. Rothschild & Co Redburn restated a “neutral” rating and set a $220.00 target price (down from $380.00) on shares of Insulet in a report on Friday, April 24th. Wells Fargo & Company lowered their target price on shares of Insulet from $360.00 to $255.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th. Barclays lowered their price objective on shares of Insulet from $286.00 to $198.00 and set an “underweight” rating on the stock in a research note on Thursday, May 7th. Weiss Ratings cut Insulet from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday, May 15th. Finally, Raymond James Financial lowered their price objective on Insulet from $355.00 to $263.00 in a research note on Thursday, May 7th. Twenty-one analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $252.04.

Insulet Price Performance

PODD stock opened at $146.01 on Thursday. The firm has a market cap of $10.11 billion, a P/E ratio of 33.96, a price-to-earnings-growth ratio of 1.22 and a beta of 1.20. Insulet has a 1 year low of $141.02 and a 1 year high of $354.88. The stock has a 50-day simple moving average of $187.01 and a 200-day simple moving average of $247.26. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. The firm had revenue of $761.70 million during the quarter, compared to analyst estimates of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.Insulet’s quarterly revenue was up 33.9% on a year-over-year basis. During the same quarter last year, the firm earned $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, equities analysts predict that Insulet will post 6.43 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Insulet

Institutional investors and hedge funds have recently made changes to their positions in the company. Winnow Wealth LLC acquired a new stake in Insulet in the 3rd quarter valued at $862,000. Nordea Investment Management AB boosted its holdings in shares of Insulet by 35.0% in the 4th quarter. Nordea Investment Management AB now owns 551,133 shares of the medical instruments supplier’s stock valued at $157,128,000 after buying an additional 142,922 shares during the last quarter. ING Groep NV grew its stake in shares of Insulet by 88.5% in the third quarter. ING Groep NV now owns 17,300 shares of the medical instruments supplier’s stock valued at $5,341,000 after buying an additional 8,123 shares in the last quarter. Machina Capital S.A.S. bought a new position in shares of Insulet in the third quarter valued at $2,778,000. Finally, Jain Global LLC increased its holdings in Insulet by 148.2% during the third quarter. Jain Global LLC now owns 106,710 shares of the medical instruments supplier’s stock worth $32,945,000 after buying an additional 63,719 shares during the last quarter.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.